Viral Clearance Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Viral Clearance Services Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The viral Clearance Services Market is Poised to grow at a CAGR of 15% over the forecast period. The major factors attributing to the growth of the market are the rising need for viral clearance and the increasing demand for specialty drugs

COVID-19 has a significant impact on the market studied. During COVID-19, the isolation of patients was the priority across the globe. A study published in the Journal of Infection and Chemotherapy in June 2021 stated that a classification of the isolation times based on age could be taken into consideration while processing the viral clearance since the length of the viral clearance periods from COVID-19 patients can vary with age. Due to biases including underlying medical disorders, it may be challenging to establish a uniform viral clearance duration for elderly patients. With the increased incidence of COVID-19, the demand for viral clearance was raised which contributed to the growth of the market.

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or approval of all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove inactivated viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house.

Biological and biotechnological products are at risk from impurities, bacteria and fungi, and viruses. With such products, the potential for transmission of viral diseases is a real risk. Viral contamination can affect raw materials, cell culture processes, bioreactor contamination, and downstream processing. It is for these reasons that pharmaceutical organizations practice viral safety and incorporate virus clearance into the manufacturing process.

Key Market TrendsRecombinant Proteins Segment is Expected to Dominate the Market During the Forecast Period

Large-scale recombinant protein production is becoming progressively critical for applications in the field of proteomics, structural biology and protein therapeutics. When large quantities of protein need to be produced cells must be cultured in large volume by the implementation of fermentation techniques. As the production of these proteins increases the demand for the viral clearance process also increases.

The major factors driving the growth of the segment are the increasing demand for biopharmaceuticals for treating chronic conditions like diabetes cancers, and these drugs are forging their ways in the field of inflammatory disease management, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases. The introduction of recombinant proteins has revolutionized the development and manufacturing processes of biotherapeutics. The number of recombinant drugs is expected to grow further as multiple biologics and vaccines consisting of recombinant proteins are currently in the pipeline and are expected to get FDA approval. Thus, considering all the above mentioned factors the market is expected to grow.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall viral clearance services market, throughout the forecast period. The largest share is mainly due to the presence of key players and their usage of advanced medical technologies to develop. The rise in the production of recombinant proteins, and vaccines and the necessity to keep them risk-free and virus-free, is the major factor for the growth of the market. Furthermore, growing awareness among the population to use biopharmaceuticals and thus increasing demand for viral clearance services.

Additionally, increasing funding for pharmaceuticals across the United States is contributing to the growth of the market studied. The American pharmaceutical industry creates a wide range of brand-new medications each year that have significant clinical advantages. Many of those medications are costly, which drives up the cost of healthcare for both the federal government and the private sector. Lawmakers have considered measures that would cut federal spending on drugs and lower drug prices. Such regulations will likely lessen the industry's incentive to produce innovative medicines. In the year 2020, the federal government in the United States invested USD 11 billion in late-stage vaccine development and expansion of manufacturing capacity through Operation Warp Speed and the Biomedical Advanced Research and Development Authority.

Hence, with the above-mentioned factors, the market for viral clearance is expected to witness strong growth in the North America region.

Competitive Landscape

The viral clearance services market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Charles River, Labor Dr. Merk & Kollegen GmbH, Texcell, Merck KGaA, WuXi AppTec, Sartorius AG, Eurofins Scientific, Bioscience Laboratories, Syngene and Vironova.

Additional Benefits:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.


1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Need of Viral Clearance
4.2.2 Rise in Research and Development Funding
4.2.3 Growing Demand for Specialty Drugs
4.3 Market Restraints
4.3.1 Lack of Approval of Outsourcing of Preclinical Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size - Value in USD million)
5.1 By Method
5.1.1 Viral Removal
5.1.2 Viral Inactivation
5.2 By Application
5.2.1 Recombinant Proteins
5.2.2 Tissue and Blood Derived Products
5.2.3 Vaccines
5.2.4 Others
5.3 By End-User
5.3.1 Biopharmaceuticals
5.3.2 Contract Research Organizations
5.3.3 Academic Research Institutes
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Charles River Laboratories, Inc.
6.1.2 Labor Dr. Merk & Kollegen GmbH
6.1.3 Merck KGaA
6.1.4 Texcell SA
6.1.5 WuXi AppTec
6.1.6 Sartorius AG
6.1.7 Eurofins Scientific
6.1.8 Bioscience Laboratories
6.1.9 Vironova
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings